Prostate Specific Antigen Velocity Threshold For Predicting Prostate Cancer In Young Men
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology; Men's health
Article Date: 26 Mar 2007 - 0:00 PDT
| Patient / Public: | ![]() |
5 (2 votes) |
| Healthcare Prof: | ![]() |
UroToday.com- Traditionally, a prostate biopsy has been recommended for patients with a PSA velocity of 0.75 ng/ml per year due to its increased association with prostate cancer. The relationship between PSA velocity and prostate cancer in young men has not been extensively studied.
In the March issue of the Journal of Urology, Loeb and colleagues from Georgetown, Northwestern, and Washington University report the results of a cohort of 6,844 men age 60 years or younger who enrolled in a prospective prostate cancer screening study. The overall prostate cancer detection rate for the cohort was 5%. Various thresholds of PSA velocity were evaluated to determine the highest predictive value for prostate cancer.
A PSA velocity threshold of 0.4 ng/ml per year or greater was independently predictive of cancer irrespective of age, total PSA, family history of prostate cancer, or race. What was most dramatic was that this criterion had the strongest association to cancer in multivariate analysis, even in patients with a total PSA less than 2.5 ng/ml. Using a PSA velocity threshold of 0.4 ng/ml/year was found to have a sensitivity of 67%, specificity of 81%, positive predictive value of 16%, and negative predictive value of 98%.
This study suggests that using a PSA velocity biopsy threshold of 0.75 ng/ml/year for men younger than 60 years may be inappropriate. Using a PSA velocity of 0.4 ng/ml/year or greater may enhance prostate cancer early detection especially in men with a total PSA lower than 2.5 ng/ml.
Loeb S, Roehl KA, Catalona WJ, Nadler RB
J Urol. 2007 Mar; 177(3):899-902 Reviewed by UroToday.com Contributing Editor Ricardo F. Sánchez-Ortiz, MD
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2006 - UroToday
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/66106.php>
APA
http://www.medicalnewstoday.com/releases/66106.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




